Isoleucine

Isoleucine

SCHEMBL3194053

CCC(C)C(N)C(=O)O.NC(=O)CC(N)C(=O)O

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 4/20 0.46
SLC1A2 P43004 4/20 0.46
SLC1A1 P43005 3/20 0.46
SLC7A5 Q01650 2/20 0.45
GRIK1 P39086 10/20 0.42
GRIA4 P48058 3/20 0.42
GRIK3 Q13003 3/20 0.42
GRIK5 Q16478 3/20 0.42
GRIK2 Q13002 6/20 0.41
GRIA2 P42262 2/20 0.41
GRIA1 P42261 1/20 0.41
ALOX15 P16050 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
GRM1 Q13255 1/20 0.38
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoleucine SCHEMBL3194059 1.00 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL4416801 1.00 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL23531111 0.98 SLC1A3 (0.44) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL23531113 0.98 SLC1A3 (0.44) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL5970331 0.96 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL15327561 0.95 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL610595 0.93 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL28445029 0.93 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL8579283 0.93 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1
Isoleucine SCHEMBL4617349 0.93 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1SLC7A5GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150752-A1 METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-09 US disclosed
US-20240141330-A1 METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-02 US disclosed
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
WO-2021151891-A1 NOVEL PHYTOENE DESATURASE VARIANTS TO PRODUCE NEUROSPORENE AND/OR ZETA-CAROTENE DEINOVE (FR) 2021-08-05 WO disclosed
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2021-02-11 US disclosed
EP-3737420-A2 STEROIDS AND ANTIBODY-CONJUGATES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2020-11-18 EP disclosed
WO-2019136487-A2 STEROIDS AND ANTIBODY-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed
EP-3237612-A1 SEQUENCE VARIANTS Sandoz AG (CH) 2017-11-01 EP disclosed
WO-2016102372-A1 SEQUENCE VARIANTS SANDOZ AG (CH) 2016-06-30 WO disclosed
US-8323961-B2 HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-12-04 US disclosed
EP-1675613-B1 HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV US GOV HEALTH & HUMAN SERV (US) 2012-05-23 EP disclosed
US-20100111998-A1 HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN 2010-05-06 US disclosed
US-7666427-B2 HIV vaccines based on Env of multiple clades of HIV THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-02-23 US disclosed
US-20080286306-A1 HIV vaccines based on Env of multiple clades of HIV GENVEC, INC. 2008-11-20 US disclosed
US-20060275897-A1 HIV vaccines based on Env of multiple clades of HIV DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY 2006-12-07 US disclosed
EP-1675613-A2 HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-07-05 EP disclosed
WO-2005034992-A2 HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIF THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 SLC1A3 3392/4885SLC1A2 3978/4885SLC1A1 3518/4885
US-11760775-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 SLC1A3 3392/4885SLC1A2 3978/4885SLC1A1 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.